1344p -98.0 -6.8%
Last Trade - 05/03/21
| Market Cap | ÂŁ557.2m |
| Enterprise Value | ÂŁ581.6m |
| Revenue | ÂŁ285.6m |
| Position in Universe | th / 1809 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 221.2 | -125.3 | 103.5 | -24.1 | 26.7 | 66.0 | -21.5% | ||||
| +158.8 | +247.9 | |||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
The Biotech Growth Trust PLC is an investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology companies. The Company will not invest more than 15%, in aggregate, of the value of its gross assets in other closed ended investment companies (including investment trusts) listed on the London Stock Exchange. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. The Company will not invest more than 10% of the value of its gross assets in direct unquoted investments at the time of acquisition. OrbiMed Capital LLC is its portfolio manager. Frostrow Capital LLP is its alternative investment fund manager.
| Last Annual | March 31st, 2020 |
| Last Interim | September 30th, 2020 |
| Incorporated | May 20, 1997 |
| Public Since | June 23, 1997 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Financials |
| Industry | Collective Investments |
| Index | FTSE All Share , FTSE All-share - Financials Price Return Gbp End Of Day, FTSE All-share - Equity Investment Instruments Price Return Gbp End Of Day, FTSE Smallcap , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 41,459,769 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 25 Southampton Buildings, LONDON, WC2A 1AL, United Kingdom |
| Web | http://www.biotechgt.com/ |
| Phone | +44 20 30084910 |
| Contact | () |
| Auditors | BDO LLP |
As of 05/03/21, shares in Biotech Growth Trust are trading at 1344p, giving the company a market capitalisation of ÂŁ557.2m. This share price information is delayed by 15 minutes.
Shares in Biotech Growth Trust are currently trading at 1344p and the price has moved by 36.59% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biotech Growth Trust price has moved by 29.7% over the past year.
Of the analysts with advisory recommendations for Biotech Growth Trust, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biotech Growth Trust is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Biotech Growth Trust is scheduled to issue upcoming financial results on the following dates:
Biotech Growth Trust does not currently pay a dividend.
Biotech Growth Trust does not currently pay a dividend.
Biotech Growth Trust does not currently pay a dividend.
To buy shares in Biotech Growth Trust you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biotech Growth Trust are currently trading at 1344p, giving the company a market capitalisation of ÂŁ557.2m.
Here are the trading details for Biotech Growth Trust:
We were not able to load our ranking data for Biotech Growth Trust
We were not able to load any forecast data for Biotech Growth Trust.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotech Growth Trust. Over the past six months, the relative strength of its shares against the market has been 0.76%. At the current price of 1344p, shares in Biotech Growth Trust are trading at -4.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biotech Growth Trust PE ratio based on its reported earnings over the past 12 months is 2.07. The shares are currently trading at 1344p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We were unable to find the directors for Biotech Growth Trust.
Here are the top five shareholders of Biotech Growth Trust based on the size of their shareholding:
